Comparative safety of JAK inhibitors versus TNF inhibitors in psoriatic arthritis: a real-world propensity score-matched cohort study.
- Published on 07/31/2026
- Reading time: 1 min.
Gautam, Naveen MBBSa,; Subedi, Bal Krishna MDb; Dhungana, Reechashree MBBSa; Pokhrel, Naveen MDc; Gupta Rauniyar, Suraj Prasad MBBSa; Surendra, K.C. MBBSd; Thapa, Sajjan Bom MBBSe
Abstract
Background: Janus kinase inhibitors (JAKi) and tumor necrosis factor inhibitors (TNFi) demonstrate therapeutic efficacy in psoriatic arthritis (PsA), yet comparative real-world safety data remain limited. This study quantified adverse outcome risks between JAKi and TNFi in PsA patients.
Methods: Retrospective cohort study utilized the TriNetX Global Collaborative Network electronic health records. Adults aged 18-99 years with PsA initiating JAKi or...
To continue reading this article in Full-Text...
* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Rheumatology
Receive our newsletter to stay up to date with the latest news in Rheumatology
More articles
From peer-reviewed journals
in Rheumatology
